Members of the ATP-dependent SWI/SNF chromatin remodeling complexes are among the most frequently mutated genes in cancer, suggesting their dysregulation plays a critical role. The synthetic lethality between SWI/SNF catalytic subunits BRM/SMARCA2 and BRG1/SMARCA4 has instigated great interest in targeting BRM. Here we have performed a critical and in-depth investigation of novel dual inhibitors (BRM011 and BRM014) of BRM and BRG1 in order to validate their utility as chemical probes of SWI/SNF catalytic function, while obtaining insights into the therapeutic potential of SWI/SNF inhibition. In corroboration of ontarget activity, we discovered compound resistant mutations through pooled screening of BRM variants in BRG1-mut cancer cells. Strikingly, genome-wide transcriptional and chromatin profiling (ATAC-Seq) provided further evidence of pharmacological perturbation of SWI/SNF chromatin remodeling as BRM011 treatment induced specific changes in chromatin accessibility and gene expression similar to genetic depletion of BRM. Finally, these compounds have the capacity to inhibit the growth of tumor-xenografts, yielding important insights into the feasibility of developing BRM/BRG1 ATPase inhibitors for the treatment of BRG1-mut lung cancers.
Introduction
The dynamic regulation of chromatin structure plays a dominant role in various important DNAdependent processes, such as gene expression, and is critical for supporting appropriate cellular states and functions (1, 2) . Extensive genetic profiling studies have unequivocally revealed a critical role for alterations in chromatin regulatory proteins in a variety of cancers. For example, mutations in members of SWI/SNF complexes, a major class of chromatin remodelers, occur at a collective frequency of almost 20%, a rate that is close to other well-established oncogenes and tumor suppressors (3) (4) (5) (6) . The SWI/SNF complexes consist of key subunits that assemble in a combinatorial fashion to remodel nucleosomes in an ATP-dependent manner, with core catalytic ATPase activity provided by the mutually exclusive and closely related subunits, BRM/SMARCA2 and BRG1/SMARCA4 (7-9). Previous studies have established cancer dependencies on SWI/SNF activity itself, creating novel opportunities for investigating its therapeutic targeting (10). For example, BRG1-mutant cancers are dependent on BRM (11-14), ARID1A-mutant cancers are dependent on ARID1B (15) and hematopoietic cancers such as AML are driven by BRG1 ATPase activity (16) (17) (18) . As a result, targeting SWI/SNF catalytic function with small molecule inhibitors has become highly attractive (18) (19) (20) (21) . In this work, we critically investigate the pharmacological activity of novel dual inhibitors of BRM and BRG1 ATPase function complementary to our recent description focused on their chemical optimization (22) .
Following the establishment of correlating biochemical, cellular pharmacodynamic and anti-proliferative activity of the compounds, we further validated their activity through the discovery of compound-resistant mutations, genome wide chromatin accessibility and transcriptional profiling, as well as surveying anti-proliferative activity in a large panel of BRG1-mut vs. wild type lung cancer cell lines. Our studies reveal first insights into the therapeutic potential of pharmacological inhibition of BRM/BRG1 ATPase activity in BRG1-mutant lung cancers, leading to well characterized probes that will be of great utility for investigating SWI/SNF activity.
Results

Small molecule inhibitors of BRM/BRG1 ATPase activity demonstrate biochemical activity against recombinant full-length BRM and a multi-subunit complex containing BRM
Given that the ATPase, but not the bromodomain activity of BRM is central in driving the growth of BRG1-deficient cancer cells (14), we initiated a small molecule hit finding and validation strategy focused on DNA-dependent ATP hydrolysis driven by a truncated yet catalytically active version of BRM (ATPase-SnAC 636-1331) ( (22) and (Fig. 1a ). To further validate the biochemical assay that was used in the screen, we tested a catalytically dead K755R BRM ATPase-SnAC protein and found no evidence of contaminating ATPase activity as it failed to hydrolyze ATP (Fig. 1b ). In addition, DNA-binding compounds are expected to be false positives in such an assay, but we confirmed that the original hit (referred to as compound 1, or BRM001) that led to the optimized dual BRM/BRG1 inhibitors BRM011 and BRM014 (Fig. 1c ), was not active in a counter-assay for DNA binding ( Supplementary Fig. 1a ). Working with a truncated, catalytically active version of BRM enabled a robust hit-finding and validation strategy but left open the question of whether hits would be competent in inhibiting the enzyme in the context of the full-length protein or a complex. We therefore developed similar biochemical assays with the full-length BRM and a multi-protein complex containing BRM and core subunits SMARCB1/ BAF47/SNF5, SMARCC1/BAF155 and SMARCC2/ BAF170
( Supplementary Fig. 1b) . Notably, compounds with varying potencies including BRM011 and BRM014 showed correlating activities against the truncated BRM and full-length BRM protein ( Fig. 1d ). Similar results were obtained with the multi-subunit complex (Fig. 1e ), indicating the potential for translation to cellular systems. Taken together, these studies further validate the in vitro activity of the inhibitors including beyond the truncated version of the enzyme.
Development and application of a BRM-ATPase dependent gene expression marker to profile cellular activity of BRM011 and related analogs
Since an important consequence of SWI/SNF chromatin remodeling activity is the regulation of gene expression, we hypothesized that specific changes in gene expression could be used to monitor the impact of chemical inhibition. We initially carried out microarray-based transcriptional profiling studies in BRG1-mutant cancer cell lines and observed that selected genes underwent significant changes in expression at early time points upon doxycycline (dox) inducible shRNA-mediated BRM knockdown (Jagani et al., U.S. patent 9,850,543 B2). Among these genes, the down regulation of KRT80 mRNA emerged as a robust marker subsequently corroborated by RNA-Seq ( Supplementary Fig. 4b ), and was followed up further due to its significant expression levels with a wide dynamic range upon BRM knockdown. Further experiments indicated that in contrast to wild-type (WT) BRM , ectopic expression of a catalytically dead ATPase mutant of BRM (K755R) is unable to rescue KRT80 gene expression upon dox-inducible BRM knockdown ( Fig. 2a and Supplementary Fig. 2a ). To determine if BRM may directly regulate KRT80 expression, we analyzed our Chromatin Immunoprecipitation coupled to deep sequencing (ChIP-Seq) studies with an antibody against BRM in the BRG1-mut H1299 cell line (23) and detected occupancy of BRM at the KRT80 locus ( Fig. 2f ). Together, these results indicate that KRT80 gene expression is dependent upon BRM ATPase function and could therefore serve as a potential pharmacodynamic (PD) biomarker for evaluating the activity of catalytic inhibitors. A large set of BRM001 analogs generated during lead optimization using chemical structure activity relationships (SAR) (including BRM011 and BRM014) with a range of potencies demonstrated significant correlation between the biochemical assay and the KRT80
RT-qPCR gene expression assay following 24 hours of compound treatment in BRG1-mut H1299 cells. (Fig. 2b, c) . To extend these findings beyond H1299 cells, BRM011 or BRM014 was tested in additional BRG1-mut cell lines including H1944, RERFLCAI and A549, resulting in similar dose-dependent modulation of KRT80 expression ( Supplementary Fig. 2b-d ). To enable a higher throughput assay for compound profiling during chemical optimization, a reporter cell line was engineered via CRISPR-mediated knock-in of Nano-Luciferase-PEST at the endogenous KRT80 locus (Fig. 2d) . A survey of BRM011 and its analogs in the KRT80 Nano-Luciferase assay recapitulated compound-induced inhibition of endogenous KRT80 gene expression as evidenced by significant correlation between the two assays ( Fig. 2d, e ). Finally, as an orthogonal method to confirm changes in gene specific chromatin remodeling, ATAC-Seq analysis showed accessible chromatin configuration at the transcriptional start site and intergenic enhancers in the 5' part and a downstream distal enhancer of the KRT80 gene consistent with BRM ChIP-Seq distribution ( Fig. 2f ), with decreased accessibility following either doxinducible BRM knockdown or 24 hours treatment with BRM011 ( Fig. 2f ). Together these studies consolidate KRT80 gene expression effects as a cellular biomarker of BRM inhibition and demonstrate that BRM011 and related analogs are capable of inhibiting chromatin accessibility and resulting gene expression driven by BRM in BRG1-mut cells.
Discovery of compound resistant mutations corroborate on-target activity
We next determined if the decrease in KRT80 mRNA induced by the inhibitors was associated with inhibition of proliferation in a BRM-dependent manner in BRG1-mut/deficient lung cancer cell lines previously shown to be sensitive to BRM knockdown (11) (12) (13) (14) . We first tested the impact of structural analogs of varying potencies on growth inhibition in the BRG1-mut A549 lung cancer cell line which was amenable to compound profiling in a 6-day proliferation assay.
Consistent with the correlation between the biochemical and cellular PD activity of the inhibitors, inhibition of the cellular PD (decreased KRT80 gene expression) also correlated with antiproliferative activity in A549 cells (Fig. 3a) . As is often a concern with small molecule inhibitors, we next investigated whether the growth inhibition observed is driven by on-target activity on BRM. While we had tested the sensitivity of target deficient SBC5 cells (lacking BRG1 and BRM) as an initial measure of on vs. off target compound activity (22), to more definitively address this, we sought to discover compound resistant mutations by screening a pooled library of BRM variants generated by error prone PCR, an approach termed functional variomics (24). We first determined that WT BRM over-expression resulted in functional expression through rescue of growth inhibition upon BRM knockdown under the conditions that would be used for the library infection (targeting approximately 1 copy per cell) (Supplementary Figs. 3a, b) . Next, we screened for compound resistant BRM variants in BRG1-mut A549 cells infected and selected to express the BRM variant library. The cells that survived compound treatment were harvested for isolation of genomic DNA, followed by PCR and next generation sequencing to identify mutations in BRM that were enriched from the library (Fig. 3b ). The most significantly enriched mutations across replicates and different compound concentrations were F897S and H860R, residues that we subsequently determined through x-ray crystallography studies as residing within the compound binding pocket in the N terminal lobe of the ATPase domain ( Fig. 3c ). In order to further validate these findings, we performed confirmatory studies by expressing BRM F897S or WT BRM as a control (Fig. 3d ), and observed significant shifts in compound sensitivity or resistance with expression of BRM F897S but not WT BRM in both short term and long term (2-week) growth assays ( Fig. 3e , f, g).
Therefore, the identification of compound resistant BRM mutations consistent with complementary structural information, substantiate on-target inhibitor activity.
BRM011 induces specific and mode-of-action related changes in chromatin accessibility and gene expression
Having established the relationship between biochemical, cellular PD and on-target growth inhibitory activity of BRM011, we further investigated the specificity of these effects through RNA-Seq and ATAC-Seq experiments in the BRG1-mutant setting. In these studies we treated H1299 lung cancer cells with BRM011 or shRNAs against BRM. As expected, the RNA-Seq analysis showed that BRM011 treatment led to robust downregulation of KRT80, with no changes in expression of BRM itself ( Supplementary Fig. 4a and Supplementary Table 1 ), while 2 independent BRM shRNAs resulted in successful knockdown of BRM expression as well as downregulation of KRT80 ( Supplementary Fig. 4b and Supplementary Table 1 ). We observed gene expression changes as early as 6 hours after compound treatment (including KRT80) and modulation of a larger number of genes after 16 hours (log2 fold-change ≥ 1 and adjusted p ≤ 0.01, Fig. 4a and Supplementary Table 1 ) of which a greater proportion were downregulated.
The profiles of gene expression changes at 16 hours of compound treatment were generally concordant with dox-inducible BRM knockdown ( Fig. 4a and supplementary Fig. 4c ). Pathway enrichment analysis also revealed various signaling cascades or processes modulated similarly between chemical inhibition and genetic knockdown, such as those associated with TNFα /NFκ B, epithelial-to-mesenchymal transition (EMT), and KRAS with some overlap of genes among the enriched pathways (Fig. 4b, c and Supplementary Fig. 4d ). Most of the genes in the KRAS signaling "up" set were downregulated, yet BIRC3 (also in the TNFα /NF-κB gene set) involved in pro-survival (25) was upregulated. Matrix metalloproteinases (MMP1/2/14) and extracellular matrix associated proteins ECM1 and SPARC were downregulated as part of the EMT gene set.
Overall, these results indicate a general agreement between the effects of BRM011 and BRM knockdown on gene expression yet reveal a potentially complex pattern of transcriptional events that precede growth inhibition (Fig. 4b,c ). In a complementary approach we used the same BRG1-mutant lung cancer model H1299 to study changes in chromatin accessibility induced by BRM011 (1 µM or 5 µM for 24 hours) or BRM knockdown (after 48 hours of Dox-induction) via ATAC-Seq ( Fig. 4d) . Of the open chromatin regions detected in the baseline untreated state, approximately 22% showed chromatin closing (> 2-fold change) upon BRM011 treatment at 1 µM, while the majority of the regions remained unperturbed indicating specific changes in accessibility induced by the inhibitor. The chromatin closing upon BRM011 treatment appeared dose-dependent ( Supplementary Fig. 4e -g), and demonstrated significant overlap (70%) with those observed upon BRM knockdown (Fig. 4e ). In addition, the regions that commonly changed in response to either compound treatment or BRM knockdown were associated with BRM binding as determined by BRM ChIP-Seq ( Fig. 4f ). Next, we linked each ATAC-Seq peak to a single target gene (see methods for the criteria used), and did observe overall downregulation of genes associated with reduced accessibility (Mann-Whitney test, p < 2.2e-16) ( Fig. 4g ). Consistently, analysis of the gene landscape associated with altered chromatin accessibility revealed similar pathway enrichments ( Supplementary Fig. 4h ) as was observed by RNA-Seq ( Fig. 4b ). To further evaluate the functional partitioning of the chromatin accessibility differences, we evaluated a subset of chromatin modifications (H3K4me1, H3K4me3 and H3K27ac) by chromatin immunoprecipitation (ChIP). These epigenetic marks play a key role in gene regulation (26-28) and together enable a functional assessment of genomic responses to SWI/SNF ATPase activity inhibition including effects on active, poised and silent genes.
Interestingly, we found that reduced chromatin accessibility tended to occur in regions of lower levels of H3K4me3 and higher levels of H3K4me1 indicating more enhancer roles ( Supplementary Figure 5a , b). Overall, histone modifications have fewer changes as compared with chromatin accessibility upon both small molecule inhibition and genetic knockdown.
However, upon further comparison of the histone marks in the regions that commonly decreased chromatin accessibility with compound treatment and BRM knockdown, we noted that a subset showed a decrease in H3K4me1 ( Supplementary Fig. 5c ). Taken together, these global profiling studies reveal that BRM011 induces changes in chromatin accessibility and gene expression that is highly consistent with BRM distribution and function providing clear evidence of their activity as inhibitors of SWI/SNF.
BRM011 and BRM014 demonstrate anti-proliferative activity in a subset of lung cancer cell lines
As BRM011and analogs are inhibitors of both BRM and BRG1 activity, we next aimed to determine their anti-proliferative activity across a panel of lung cancer cell lines that were BRG1mutant and lacked BRG1 expression, or express both BRG1 and BRM, as verified by western blotting (Fig. 5a ). A 10-12 day colony formation assay ( Supplementary Fig. 6a -c), was used to assess compound responses across 29 lung cancer cell lines. While one could hypothesize that a dual BRM and BRG1 inhibitor would exert pan-lethal effects independent of the BRG1 status, we interestingly observed that this was not generally the case (Fig. 5b) . In fact, a majority of BRG1-WT cancer cell lines tested were refractory or modestly sensitive to compound treatment.
On the other hand, the BRG1-mutant cancer cell lines clustered in two groups, revealing a range of sensitivity to BRM011. Notably, the inherent growth rate of the cell lines was not the reason for the differential sensitivity between BRG1-mutant and WT cancer cell lines, since we did not observe a correlation between cell line doubling time and sensitivity to compound treatment ( Supplementary Fig. 6d ). We also noted that in an example of a BRG1-WT line that was not sensitive to the compound, there was a corresponding lack of growth inhibition with dual BRM/BRG1 knockdown ( Supplementary Fig. 6 e, f). In further validation of the overall findings, we tested a subset of the cancer cell line panel for sensitivity to BRM014, a closely related analog of BRM011 with similar potency, and observed a significant correlation of response between these two inhibitors ( Fig. 5c ). Furthermore, the heightened sensitivity in some of the BRG1-mutant cell lines is less likely to be explained by cell line specific off-target activities since BRM017, a cell permeable yet a poorly active structural analog ( Fig. 5d ), failed to induce growth responses at similar concentrations to those observed for BRM011 and BRM014 ( Fig. 5e , f). In selected examples of BRG1-WT cell lines dual knockdown of BRM and BRG1 recapitulated moderate compound sensitivity ( Supplementary Fig. 5g , h). While the reason for modest responses in some BRG1-mutant lines is not clearly understood, the overall results reveal that the genetic dependence on SWI/SNF (BRM/BRG1) generally corresponds with antiproliferative responses through chemical inhibition thus validating these inhibitors as tools for more broadly probing SWI/SNF dependency even beyond BRG1-mutant cancers.
BRM011 and BRM014 inhibit growth of BRG1-mutant lung tumor xenografts with potential for on-target toxicity in the gastrointestinal tract
Following the elucidation of BRM011 and BRM014 activity in vitro, we further studied their potential to inhibit the growth of BRG1-mutant lung cancer xenografts in vivo. Given the observation that some BRG1-mutant cancer cell lines were exquisitely sensitive to compound treatment in vitro e.g. RERFLCAI (BRM 011 AAC 50 = 0.02 µM), whereas others were moderately sensitive e.g. NCIH1299 (BRM 011 AAC 50 = 0.8 µM) ( Fig. 5b) , we compared tumor growth inhibitory activity between H1299 to the results obtained in RERFLCAI (22) . H1299 lung tumor xenografts were treated once daily with the vehicle, BRM011 (30 mg/kg), BRM014
(7.5 mg/kg, 20 mg/kg) or intermittently with BRM014 (30 mg/kg 4 days on-3 days off). The lower dose of 7.5mg/kg of BRM014 did not result in anti-tumor activity, whereas the 20 mg/kg dose of BRM014 which was also well tolerated, modestly inhibited tumor growth (T/C of 50.1%) ( Fig. 6a, b ), and the intermittent dosing producing a similar albeit greater tumor growth inhibition (T/C of 39.4%). The continuous 30 mg/kg treatment of BRM011 however led to significant tumor growth inhibition (T/C of 30.7%), yet this was accompanied by body weight loss after approximately 7 days of daily dosing ( Fig. 6b ). From every treatment group, tumors were collected at several time points following the last dose to examine the extent of target inhibition (PD) through measurement of BRM-dependent KRT80 gene expression ( Fig. 6c ). We were able to validate the use of KRT80 as a tumor PD marker in vivo, as its mRNA decreased by approximately 90% upon BRM knockdown in H1299 tumor xenografts ( Supplementary Fig. 7a ) with BRM knockdown leading to tumor stasis in this model (11) . In response to compound treatment, KRT80 gene expression was maximally suppressed by ~60-80% at 7 hours after the last dose with relatively less suppression (~40-60%) observed at 16 and 24 hours ( Fig. 6c ). Of note, 30mg/kg of BRM011, which was not well tolerated led to relatively greater inhibition of KRT80 expression. Together, these results indicate that with the tolerated dosing regimen used for BRM014 (20 mg/kg, once daily), the extent and durability of target inhibition was likely not complete and could delay but not fully suppress tumor growth. In comparison, such a dosing regimen yielded a similar level of tumor growth inhibition in the BRG1-mut RERFLCAI tumor model which was approximately 40-fold more sensitive to the inhibitors in vitro. These results suggest that in vivo sensitivity may be uncoupled from the level of in vitro sensitivity and a high level of target inhibition is required in the BRG1-mut setting for efficacy in vivo.
To investigate the potential factors contributing to the decreased tolerability observed with 30 mg/kg BRM011 treatment, we collected tissue samples of major organs (15 tissues -see methods)
in this dose group and in vehicle treated animals. To evaluate systemic target engagement, PD modulation and support tissue based evaluation, we first evaluated the chromatin accessibility changes in mouse white blood cells (vehicle and 30mg/kg treated) through ATAC-sequencing.
We found significant chromatin remodeling, with a majority of reduced accessibility sites, overall consistent with chromatin effects observed in tumor cells and providing evidence of target modulation in vivo in normal tissue ( Supplementary Fig. 7b ). The microscopic assessment of the selected tissues specifically highlighted BRM011-related degenerative changes in the gastrointestinal tracts (GITs) from all BRM011 treated animals ( Fig. 6d ). The most characteristic change in the GIT was altered villus architectures characterized by villus fusion/clubbing with loss of discrete crypt structures. The intestinal epithelial cells were composed of relatively immature cells represented by increased cytoplasmic basophilia and large nuclei as well as decreased goblet cell populations. In the large intestine of some animals, there were ulcerations as well. The changes in the GITs were likely to be a contributing factor to the body weight decrease.
BRG1 has been previously shown to play a critical role in small intestinal stem cell homeostasis (29). In particular, VillinCreER T2 mediated knockout of Brg1 in mice led to lethality associated with a significant disruption of the crypt-villus architecture and a decreased expression of crypt stem cell markers such as Olfm4 in the small intestine (29). We thus evaluated the expression of Olfm4 through immunohistochemistry (IHC) staining, and consistent with the transgenic mouse model, observed a marked reduction in its expression in the intestinal crypts from BRM011 treated animals ( Fig. 6e ). Serial section evaluation of Brg1 and Ki67 protein expression and distribution did not highlight significant expression differences between BRM011 treated and vehicle controls. Olfm4 downregulation without apparent increase in Ki67 expression indicated that the microscopic finding of increased immature epithelial cells (e.g. basophilia) in GITs was likely due to impaired maturation rather than regenerative hyperplasia for repairing damaged intestines. Therefore, the consistency between the histopathological effects of the inhibitor and Brg1 knockout mice are suggestive of on-target activity as the underlying basis of the GIT changes and body weight loss. Overall, our studies importantly demonstrate the potential for pharmacological inhibition of SWI/SNF to cause tumor growth inhibition in the BRG1-mutant setting in vivo, while providing critical insights into the potential consequences of systemic dual BRM/BRG1 inhibition.
Discussion
As SWI/SNF mutations commonly occur in cancers and genetic context-specific dependencies on different subunits play an important role in tumor cell survival, the prospect of targeting SWI/SNF has emerged as an intense area of investigation and holds great promise for future therapies (19) (20) (21) 30) . The translation of cancer dependencies arising from SWI/SNF such as that of catalytic inhibition of BRM in BRG1-deficient lung cancers has remained unexplored. In this study, we elucidate the activity of dual BRM/BRG1 ATPase inhibitors in various BRG1-mut lung cancer models and provide critical evidence for their function as novel probes of SWI/SNF remodeling activity both in vitro and in vivo. This is distinct from the degradation approach that has been recently described in vitro with heterobifunctional chemical tools that induce degradation of BRM, BRG1 and PBRM1 and it remains to be determined if sufficient BRM degradation can be achieved for anti-tumor efficacy in vivo (30). Even though BRM011 and BRM014 are dual inhibitors, we reasoned that we could effectively employ such molecules to answer key questions. These include the feasibility of small molecule inhibition of SWI/SNF catalytic activity in cells, the ability of chemical inhibition to broadly recapitulate the genetic synthetic lethality in BRG1-deficient cancers, and understanding whether dual inhibition can afford a therapeutic window in this context.
Selectivity is a critical consideration when employing small molecule inhibitors and we were able to confirm on-target anti-proliferative effects of BRM011 through the discovery of compound resistant variants of BRM (F897S and H860R) using a functional variomics screening approach in a BRG1-mutant lung cancer model. These residues were independently determined and found to reside in the compound binding pocket in a co-crystal structure of a BRM011 analog in complex with the N-terminal lobe of the ATPase domain of BRM (22). While the development of KRT80 gene expression as a cellular PD marker of SWI/SNF activity enabled swift tracking of chemical SAR and excellent concordance with biochemical activity, we also carried out broader studies to inform changes in chromatin accessibility (via ATAC-Seq) and gene expression (RNA-Seq) with BRM011 treatment. Our results reveal specific changes in chromatin accessibility and gene expression elicited by BRM011 while also showing concordance with genetic inhibition, thereby providing critical validation of pharmacological activity. In order to further study the potential for BRM011 and analogs to target the growth of BRG1-deficient lung cancer cells, we profiled a large panel of lung cancer cell lines with either BRG1 WT or mutant/deficient status. This analysis revealed several key points. First, even though dual BRM/BRG1 inhibition may have been expected to be generally cytotoxic, a majority of BRG1 WT lung cancer cell lines was insensitive, or modestly sensitive, suggesting that the BRG1-mutant state potentially creates increased dependency on the remaining SWI/SNF activity driven by BRM. Second, as SWI/SNF dependency may exist in cancers without SWI/SNF mutations, the subset of BRG1 wild type cell lines sensitive to the inhibitors requires further investigation. Of note, we were able to observe that dual knockdown of BRM and BRG1 induced growth inhibition in these cells, consistent with compound sensitivity. Finally, in the BRG1-mutant cell lines, there was a significant enrichment in sensitivity. While the determinants of the in vitro sensitivity in BRG1-mutant lines is not fully understood and will demand further investigation, our in vivo results indicate that a high level of sustained and durable target inhibition is required for efficacy in vivo.
These studies provide critical insights into the therapeutic utility of targeting BRM/BRG1 catalytic function for several potential applications. In the BRG1-mutant lung cancer models that were tested, significant target inhibition (measured through KRT80 gene expression) is required for producing anti-tumor responses in vivo. Our ability to administer doses that could achieve greater target inhibition, as evidenced by KRT80 mRNA, was limited by tolerability with repeated dosing. Although we cannot completely rule out off-target effects of the compound in vivo, our results indicate a potential on-target effect related to the toxicity in the gastro-intestinal tract similar to what has been observed with the Brg1 knockout in the intestinal epithelium (29).
Such findings reveal important considerations for BRM inhibition in the BRG1-mutant context, suggesting that future efforts to generate BRM selective inhibitors, including via a degradation approach will likely require potent inhibitors while maintaining selectivity over BRG1. On the other hand, SWI/SNF (including BRG1 itself) has also been studied as a potential target in other cancers leaving open the possibility that in other tumor contexts lower levels of SWI/SNF inhibition may be required to elicit an effective anti-tumor response. Further, given the emerging role of SWI/SNF in resistance to cancer immunotherapy (31,32), these studies provide important insight on modulation of SWI/SNF activity in vivo, providing tools for further exploring the potential for SWI/SNF inhibition in this context. Overall, these studies form the groundwork for further pursuit of SWI/SNF targeting strategies, and the comprehensively validated novel small molecule inhibitors described herein will be invaluable in elucidating the role of SWI/SNF in disease and charting new paths towards novel therapies.
Methods
Expression and purification of BRM full-length and SWI/SNF complex tetramer
Full-length BRM construct (C-terminal 6xHis and C-terminal FLAG-6xHis tag) was produced in Spodoptera frugiperda (Sf9) 
Compound synthesis and Characterization
BRM011 and BRM014 were synthesized as described in our recently published work (22) and dissolved in DMSO. The synthesis of BRM017, used as a control analog in these studies is described in the supplementary methods.
Cell Lines, BRM and BRG1 shRNAs, Antibodies and Western Blotting
Cell lines used and their sources are listed in Supplementary Table 2 . The dox inducible control shRNA (also referred to as non-targeting control (NTC)), or shRNAs targeting BRM, or BRG1, including validation of knockdown in the stably selected versions of BRG1-mutant cancer cell lines A549 and H1299 have been previously described (11). Antibodies against BRM or BRG1 for western blotting have been previously described (11).
Overexpression/shRNA studies for BRM ATPase-dependent gene expression
BacMam baculovirus engineered for expression of codon optimized/shRNA resistant wild type BRM or BRM ATPase dead (K755R) expression in mammalian cells was generated by Ct values were recorded (Applied Biosystems 7900HT), and IC 50 for compounds were determined using an in house statistics package (HELIOS).
Cell Proliferation Assay
A549 cells were plated at 150 cells per well in 50 µL in 384 well plates (Costar). The following day, cells were treated with compound at 10 point 3 fold dilution starting down from 10 µM then assayed after 6 days. Growth inhibition was determined by quantifying the ATP concentration using Cell Titer-Glo® Luminescent Cell Viability Assay (Promega), followed by luminescence acquisition (Wallac Envision plate reader). IC 50 for compounds were determined using an in house statistics package (HELIOS).
Compound Resistant Mutation Studies
Variant Library Generation
The BRM ORF (isoform NP_003061) was codon-optimized, synthesized (Invitrogen, Carlsbad, CA), and cloned into vector pXP1704 (lentiviral, with EF1alpha promoter driving BRM expression) using NotI and AscI restriction enzymes (New England Biolabs, Ipswich, MA).
Error-prone PCR was performed on the 2,767bp region of the ORF between residue V685 and the stop codon, using the Ex Taq DNA Polymerase (Takara Bio USA, Mountain View, CA) with the addition of 10 µM MnCl 2 to the reaction (24). This served to both amplify this region of the ORF and to introduce mutations, targeting one non-silent mutation per amplicon. The mutated amplicon pool was restriction-cloned, along with a no-insert control, back into the pXP1704-BRM plasmid using SalI and AscI restriction enzymes, in order to create a library pool of variomics clones. This pool was transformed into XL10 Gold E. coli cells (Agilent Technologies, Santa Clara, CA), targeting a library size of at least 16,600 transformants (i.e. large enough to mutate every nucleotide in the 2,767bp target region of the ORF at least once, and then doubled to account for clones not carrying mutations). The final mutant library was determined to contain about 49,000 clones (3x the desired coverage). 40 colonies were selected for DNA prep and Sanger sequencing in order to infer the mutation rate of the library, which was found to be approximately 0.70 non-silent mutations per clone (i.e. on average, 70% of clones in the library contain at least 1 non-silent mutation, and the rest contain either no mutation or a silent one).
Virus production of the variant library is described in the supplementary methods.
Variant Library Infection and Compound Treatments
Given estimated size of the BRM library at approximately 40-50K variants, infections were designed to achieve a representation of 25 cells per variant. 1x10 6 A549 cells were plated in 150 mm dishes (in biological duplicate) and infected with 400 µL virus of the BRM variant library overnight. The following day the medium was replaced and 1 mg/mL of neomycin was added for 5 days. Cells surviving selection were collected (14.7 x10 6 cells) and 0.5 x10 6 cells were plated in 150 mm dishes for compound screening and 0.05x10^6 cells in six well plates for visualization. Compound treatment (with BRM011) was performed in biological duplicates at 2.5, 5, 7.5, 10 and 15 µM vs. DMSO control. Wild type BRM virus infected cells were used as controls for compound treatment. Compound treatments continued over 3 weeks (with a weekly medium and compound exchange) when there was a clear differential in surviving cells between BRM WT control treated cells and the variant library infected cells. Genomic DNA extraction and PCR is described in the supplementary methods. Resulting reads were aligned a second time but this time without 'hard-clipping. Reads were then subjected to variant calling using the VarDict variant calling algorithm (34) using default parameters except for the AF value which was set to AF = 0.0001. Variants identified in the ORF, above an arbitrary threshold frequency of 1.5%, detected in at least two of the three PCR replicates generated per condition were reported. Nucleotide variants were translated into amino acid changes using standard methods.
NGS and Analysis of Enriched BRM Variants
Differential Expression and Pathway Enrichment Analysis
Differential expression was determined using DESeq (PMID: 20979621). Genes were called differentially expressed if they had an average expression >= 1 (reported as AveExpr, a TMMnormalized unit of expression, in DESeq), an adjusted p-value <= 0.01, and an absolute Log 2 fold-change of 0.5 relative to DMSO control. We performed gene set enrichment analysis for differentially expressed genes using the hypergeometric test with FDR-adjusted p-values for 2 pathway sets downloaded from MSigDB (PMID:16199517; Hallmark and KEGG).
ATAC (Assay for Transposase-Accessible Chromatin)-Sequencing
ATAC-Seq was performed as previously described (35) aligned onto human genome (hg19) using Bowtie2 with parameters "--local -X 1000". The two ends of reads were counted as two independent chromatin cuts. For ATAC-Seq signal, genomewide cut frequency profiles were derived by counting the number of cuts within a 150 bp window in 25 bp step after normalizing to 10 million total cuts. Open chromatin regions are defined as peaks of normalized cut frequency. First, a position was called significant if the normalized cut count is greater than 6 (~10 fold higher than the background), and significant positions within 150 bp were merged and extended to peaks. In total, 39,355 peaks identified in H1299 cell line . These peaks were linked to their target genes as: 1) if the peak is within a gene body, the gene is defined as its target without considering the distance between the peak and gene's TSS, 2) if the peak is outside of any gene body, gene with the nearest TSS is defined as its target. Pathways that are enriched by certain sets of genes were identified by hypergeometric test based on pathway annotation from MSigDB. Custom code for ATAC-Seq data analyses used in this work is available upon request.
In vivo efficacy and pharmacodynamics
Mice were maintained and handled in accordance with the Novartis Institutes for BioMedical Research (NIBR) Institutional Animal Care and Use Committee (IACUC) and all studies were approved by the NIBR IACUC. NCI-H1299 tumor xenografts were generated by implanting 
Necropsy, histopathology analysis and immunohistochemistry staining
Separate cohorts of animals bearing NCI-H1299 tumor xenografts were treated with either vehicle or 30 mg/kg BRM011 once daily and were subjected to necropsy and histopathological analysis. Animals were sacrificed by carbon dioxide inhalation after 11 -13 days of BRM011 and 18 days of vehicle treatment and necropsy was performed. Tissues (artery, adrenal gland, heart, kidney, cecum, colon, liver, lung, pancreas, duodenum, ileum, jejunum, spleen, stomach and diaphragm) were collected in 10% neutral buffered formalin for fixation and subjected to microscopic evaluation and immunohistochemistry (IHC) analysis after timed fixation.
Histopathology analysis and immunohistochemistry staining
Formalin fixed and paraffin embedded mouse intestinal tissues blocks were sectioned at 4 micrometer thickness and collected on SuperFrost Plus slides. IHC for the proliferation marker (Ki67), the stem cells marker (Olmf4) and BRG1 was performed in the automated stainer Ventana Discovery XT using the procedure Res IHC DAB Map XT or Res IHC Omni-UltraMap HRP XT. After dewaxing, antigen demasking was performed in either EDTA-based or citratebased buffer (CC1 solution or RiboCC solution, Roche Diagnostics, Rothkreuz Switzerland).
The primary antibodies were incubated on tissue sections for 3 or 6 hours at room temperature followed by application of a secondary biotin-conjugated donkey anti-rabbit diluted at 1/500 or a multimer UltraMap anti-Rabbit HRP conjugated. A chromogenic detection was performed using either the DABmap® kit or the ChromoMap® kit from Roche Diagnostic AG (Rotkreuz, Switzerland). Details for primary antibodies and staining protocol are included in the supplementary methods. All the slides were dehydrated and mounted using Pertex® after the staining and scanned on the NanoZoomer 2,0-HT scanner instrument (Hamamazu Photonics France, Massy, France) using the x40 objective.
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